Business
Argenx to Buy Forte Biosciences for $2.2 Billion, Adding a First-in-Class Antibody
The deal hands Argenx FB102, an anti-CD122 antibody with early data in vitiligo and celiac disease, deepening its push into autoimmune diseases.